Institute of Forensic Medicine, University of Wuerzburg, Versbacher Str. 3, 97078, Wuerzburg, Germany.
Institute of Biochemistry and Molecular Biology I, Biozentrum - Am Hubland, 97074, Wuerzburg, Germany.
Int J Legal Med. 2021 Jan;135(1):183-191. doi: 10.1007/s00414-020-02462-2. Epub 2020 Nov 12.
In the last few years, quantitative analysis of metabolites in body fluids using LC/MS has become an established method in laboratory medicine and toxicology. By preparing metabolite profiles in biological specimens, we are able to understand pathophysiological mechanisms at the biochemical and thus the functional level. An innovative investigative method, which has not yet been used widely in the forensic context, is to use the clinical application of metabolomics. In a metabolomic analysis of 41 samples of postmortem cerebrospinal fluid (CSF) samples divided into cohorts of four different causes of death, namely, cardiovascular fatalities, isoIated torso trauma, traumatic brain injury, and multi-organ failure, we were able to identify relevant differences in the metabolite profile between these individual groups. According to this preliminary assessment, we assume that information on biochemical processes is not gained by differences in the concentration of individual metabolites in CSF, but by a combination of differently distributed metabolites forming the perspective of a new generation of biomarkers for diagnosing (fatal) TBI and associated neuropathological changes in the CNS using CSF samples.
在过去的几年中,使用 LC/MS 对体液中的代谢物进行定量分析已成为实验室医学和毒理学中的一种既定方法。通过制备生物标本中的代谢物图谱,我们能够在生化水平上理解病理生理机制,从而理解功能水平上的机制。一种创新的研究方法,尚未在法医背景下广泛使用,是使用代谢组学的临床应用。在对 41 份死后脑脊液 (CSF) 样本进行的代谢组学分析中,我们将样本分为心血管死亡、孤立性躯干创伤、创伤性脑损伤和多器官衰竭这四个不同死因的队列,我们能够在这些不同组之间识别出代谢物图谱的相关差异。根据这一初步评估,我们假设 CSF 中单个代谢物浓度的差异并不能提供生化过程的信息,而是通过形成新一代生物标志物的不同分布代谢物组合来提供信息,这些生物标志物可用于使用 CSF 样本诊断(致命)TBI 和相关的中枢神经系统神经病理学变化。